MaxCyte (MXCT) News Today → America could fall from this event (From Porter & Company) (Ad) Free MXCT Stock Alerts $4.71 -0.03 (-0.63%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 3:53 AM | americanbankingnews.comFY2024 EPS Estimates for MaxCyte, Inc. Increased by Analyst (NASDAQ:MXCT)May 12 at 11:47 PM | marketbeat.comRoubaix Capital LLC Invests $1.82 Million in MaxCyte, Inc. (NASDAQ:MXCT)Roubaix Capital LLC purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 386,201 shares of the company's stock, valued at approximately $1,815,000. RMay 11 at 5:58 AM | americanbankingnews.comWilliam Blair Comments on MaxCyte, Inc.'s Q1 2025 Earnings (NASDAQ:MXCT)May 10, 2024 | marketbeat.comMaxCyte, Inc. Forecasted to Post Q1 2025 Earnings of ($0.14) Per Share (NASDAQ:MXCT)MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of MaxCyte in a research report issued to clients and investors on Wednesday, May 8th. William Blair analyst M. Larew anticipates that the company will earn ($0May 8, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Sees Large Volume IncreaseMaxCyte (NASDAQ:MXCT) Sees Unusually-High Trading VolumeMay 8, 2024 | lse.co.ukMaxCyte shares rise amid double-digit revenue increaseMay 8, 2024 | finance.yahoo.comMaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...May 7, 2024 | investorplace.comMXCT Stock Earnings: MaxCyte Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 7, 2024 | globenewswire.comMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 GuidanceMay 3, 2024 | morningstar.comMaxCyte Inc MYE0April 26, 2024 | finance.yahoo.comMaxCyte, Inc. (MXCT)April 23, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Receives Overweight Rating from StephensStephens restated an "overweight" rating and set a $11.00 price objective on shares of MaxCyte in a research report on Tuesday.April 10, 2024 | globenewswire.comMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024April 5, 2024 | msn.comMesa Laboratories maintains quarterly dividend of $0.16April 2, 2024 | globenewswire.comMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)March 29, 2024 | insidertrades.comInsider Selling: MaxCyte, Inc. (NASDAQ:MXCT) Director Sells 5,000 Shares of StockMarch 28, 2024 | marketbeat.comJohn Joseph Johnston Sells 5,000 Shares of MaxCyte, Inc. (NASDAQ:MXCT) StockMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 5,000 shares of the firm's stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $4.41, for a total value of $22,050.00. Following the transaction, the director now directly owns 120,583 shares in the company, valued at approximately $531,771.03. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 20, 2024 | marketbeat.comWillis Investment Counsel Invests $2.59 Million in MaxCyte, Inc. (NASDAQ:MXCT)Willis Investment Counsel purchased a new position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 550,000 shares of the company's stock, valued at approximately $March 17, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near TermMarch 15, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 14, 2024 | finance.yahoo.comMaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 13, 2024 | marketbeat.comMaxCyte (NASDAQ:MXCT) Receives Outperform Rating from William BlairWilliam Blair reissued an "outperform" rating on shares of MaxCyte in a research report on Wednesday.March 13, 2024 | marketwatch.comMaxCyte Shares Rise 13% After 4Q Beat, Reaffirmed GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 12, 2024 | globenewswire.comMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 GuidanceMarch 6, 2024 | finanznachrichten.deMaxCyte, Inc.: MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 5, 2024 | marketbeat.comWilliam Blair Reiterates "Outperform" Rating for MaxCyte (NASDAQ:MXCT)William Blair reissued an "outperform" rating on shares of MaxCyte in a report on Tuesday.March 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsMarch 4, 2024 | globenewswire.comMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary ResultsFebruary 19, 2024 | marketbeat.comBlair William & Co. IL Boosts Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)Blair William & Co. IL increased its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 94.4% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,851 shares of the company's stock afteFebruary 16, 2024 | marketbeat.comMaven Securities LTD Buys New Position in MaxCyte, Inc. (NASDAQ:MXCT)Maven Securities LTD bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 204,175 shares of the company's stock, valued at approximately $637,000.February 9, 2024 | finance.yahoo.comMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor ConferencesJanuary 30, 2024 | finance.yahoo.comMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for CancersJanuary 23, 2024 | markets.businessinsider.comMaxCyte Signs SPL Agreement With ImugeneJanuary 9, 2024 | msn.comWhy Cell Engineering Company MaxCyte Shares Are Up TodayJanuary 9, 2024 | seekingalpha.comCOMM, NKTX and AVIR are among after hour moversJanuary 5, 2024 | benzinga.comMaxCyte Stock (NASDAQ:MXCT) Dividends: History, Yield and DatesJanuary 3, 2024 | finance.yahoo.comMaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell PipelineJanuary 2, 2024 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Sees Significant Growth in Short InterestMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 4,000,000 shares, an increase of 29.9% from the November 30th total of 3,080,000 shares. Approximately 4.4% of the company's stock are sold short. Based on an average trading volume of 1,050,000 shares, the short-interest ratio is currently 3.8 days.January 2, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorJanuary 2, 2024 | msn.comMaxCyte gets new CEO and PresidentJanuary 2, 2024 | finance.yahoo.comMaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and DirectorDecember 28, 2023 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Director John Joseph Johnston Sells 5,000 SharesMaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) Director John Joseph Johnston sold 5,000 shares of the business's stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $4.53, for a total value of $22,650.00. Following the sale, the director now owns 120,583 shares in the company, valued at approximately $546,240.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.December 15, 2023 | finance.yahoo.comWith 74% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsDecember 14, 2023 | marketbeat.comFY2023 EPS Estimates for MaxCyte, Inc. (NASDAQ:MXCT) Raised by AnalystMaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Equities research analysts at William Blair increased their FY2023 EPS estimates for MaxCyte in a research note issued to investors on Tuesday, December 12th. William Blair analyst M. Larew now anticipates that the company will post earnings per share oDecember 11, 2023 | marketwatch.comMaxCyte Names Maher Masoud CEODecember 11, 2023 | msn.comMaxCyte announces departure of founder and CEO Doug DoerflerDecember 11, 2023 | markets.businessinsider.comMaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023December 11, 2023 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Stock Holdings Trimmed by Blue Water Life Science Advisors LPBlue Water Life Science Advisors LP trimmed its position in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 41.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,885,000 shares of the company's stock af Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. MXCT Media Mentions By Week MXCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MXCT News Sentiment▼0.980.57▲Average Medical News Sentiment MXCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MXCT Articles This Week▼161▲MXCT Articles Average Week Get MaxCyte News Delivered to You Automatically Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MeiraGTx News OmniAb News Absci News Harvard Bioscience News Inotiv News Anika Therapeutics News TScan Therapeutics News Beauty Health News Bioventus News Tourmaline Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MXCT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityThe only AI company you should be looking atBehind the MarketsNo experience to confident trader, meet my student…Wealth Builders InstituteCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOIC Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MaxCyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
